This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations
Scientific Reports Open Access 28 July 2017
-
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
Leukemia Open Access 23 May 2016
-
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia
Journal of Hematology & Oncology Open Access 12 December 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL et al. Array-based genomic resequencing of human leukemia. Oncogene 2010; 29: 3723–3731.
Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424–2433.
Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011; e-pub ahead of print 18 March 2011.
Abdel-Wahab O, Pardanani A, Patel J, Wadleigh M, Lasho T, Heguy A et al. Concomitant analysis of ASXL1 and EZH2 mutations in myelofibrosis, chronic myelomonocytic leukemia, and blast-phase myeloproliferative neoplasms. Leukemia 2011; e-pub ahead of print 01 April 2011.
Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703–1708.
Acknowledgements
This work was supported in part by grants from the Gabrielle's Angel Foundation and from the Starr Cancer Consortium to RLL. RLL is an Early Career Award Recipient of the Howard Hughes Medical Institute and is a Geoffrey Beene Junior Faculty Chair at Memorial Sloan Kettering Cancer Center.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Abdel-Wahab, O., Pardanani, A., Rampal, R. et al. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 25, 1219–1220 (2011). https://doi.org/10.1038/leu.2011.82
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.82
This article is cited by
-
Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms
Leukemia (2018)
-
Epigenetic changes in myelofibrosis: Distinct methylation changes in the myeloid compartments and in cases with ASXL1 mutations
Scientific Reports (2017)
-
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
Leukemia (2016)
-
Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells
Leukemia (2016)
-
DNA methylation in normal and malignant hematopoiesis
International Journal of Hematology (2016)